- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | iRegene Therapeutics's NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa | ||
| Do | AI biotech Iambic aims for $135M IPO to push cancer drugs through clinic | ||
| Do | Endeavor's threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor | ||
| Do | 'It's just survival now': Why is almost a third of Boston's life sciences lab space sitting vacant? | ||
| Do | Zealand Pharma, Roche's 'intriguing' weight loss for amylin drug soured by blood sugar data | ||
| Do | Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave's asset | ||
| Do | Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run | ||
| Mi | Cadrenal launches strategic review for late-stage cardiology pipeline | ||
| Mi | ARPA-H unveils Surpass program to accelerate and expand clinical trials | ||
| Mi | TCGX launches $600M fund to bankroll Asian biotechs | ||
| Mi | Cerevance rescues its Parkinson's drug with phase 3 win | ||
| Mi | Atsena's Lighthouse gene therapy readout illuminates eye disease efficacy | ||
| Mi | Matchpoint nets $150M series B to take covalent med into clinic | ||
| Mi | MimiVax's cancer vaccine fails phase 2 glioblastoma study, but CEO still sees data as 'inspiring' | ||
| Di | Nuvig halts development of lead drug for rare autoimmune disease | ||
| Di | How NIH's Kleinstreuer reduces animal tests without 'backlash' | ||
| Di | Mimetic's peptide shows promise in reducing neuropathic pain | ||
| Di | ArriVent's phase 3 lung cancer trial flops, sinking stock | ||
| Di | Kairos seizes moment to push cancer asset into earlier setting | ||
| Di | Forbion's 'landmark' €2.3B fundraise to benefit 30 biotechs | ||
| Di | AstraZeneca hopes for 'amazing things' from Kendall Square R&D center | ||
| Di | TRex eyes $111M IPO, as Retension and Lycia also look to Nasdaq | ||
| Mo | Gate CEO sees expanded $870M Lilly pact as 'vote of confidence' | ||
| Mo | Trio of scientists win Nobel Prize for neuron light switch work | ||
| Mo | 4 Criteria for Choosing the Right Biologics CDMO |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.